Results 81 to 90 of about 230,574 (171)

Orbital decompression in Graves` orbitopathy

Medicinski pregled, 2012
Introduction. This paper was aimed at presenting our experience and results in the surgical management for proptosis in patients with Graves` orbitopathy. Material and Methods. This is a retrospective, interventional, non-comparative case series review.
Miroslav, Knezević, Branislav, Stanković, Dejan M, Rasić, Milos, Zarković, Jasmina, Cirić, Biljana, Beleslin   +5 more
openaire   +3 more sources

TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy

Archives of Endocrinology and Metabolism
Objective Thyrotoxicosis is established risk factor for osteoporosis due to increased bone turnover. Glucocorticoids often administered for Graves' orbitopathy (GO) have additional negative effect on bone mineral density (BMD). Our aim was to examine the
Mira Siderova, Kiril Hristozov, Aleksandra Tsukeva   +2 more
doaj   +1 more source

Graves’ orbitopathy: the importance of statin therapy [PDF]

Background. Graves’ orbitopathy is the most common extrathyroidal autoimmune disorder, predominantly caused by hyperthyroidism. Prevention and development of an individualized treatment plan involve the use of statins and the management of risk factors:
Rizov, Cristina, Tidvă, Adelina
core  

What\u27s New in Graves\u27 Orbitopathy?

, 2018
Graves\u27 orbitopathy (GO) is the most frequent extrathyroidal manifestation of Graves\u27 disease (GD). Depending upon the diagnostic criteria used up to 50% of patients with GD have ophthalmic findings; with lid retraction/lid lag being the most ...
Jim Garrity, MD
core   +1 more source

Unilateral Graves’ Orbitopathy in a Patient with Marine-Lenhart Syndrome: A case report

Sultan Qaboos University Medical Journal
Thyroid eye disease (TED) is the most common symptoms of Graves’ disease. This condition commonly manifests bilaterally and symmetrically. The most prominent symptoms are lid retraction, exophthalmos and diplopia. Rarely, individuals with Graves’ disease
Abdulla Alfutaisi, Alaa Osman, Zainab S Al Siyabi, Osama S Al Senani, Fatima Bahowairath, Ahmed Al Farqani, Sara K Al Rasbi   +6 more
doaj   +1 more source

Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question

, 2017
There is a general belief that Graves' orbitopathy (GO) is a "chronic" disease, namely that patients' eyes do not return to how they were before GO appeared.
Elena Sabini, Rocchi, Roberto, Michele Marinò, Paolo Vitti, Mazzi, Barbara, Sabini, Elena, Latrofa, Francesco, Leo, Marenza, Barbara Mazzi, Vitti, Paolo, Marenza Leo, Claudio Marcocci, Marcocci, Claudio, Nardi, Marco, Marinò, Michele, Marco Nardi, Francesco Latrofa, Roberto Rocchi   +17 more
core   +1 more source

Graves’ orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia – side effect of alemtuzumab therapy?

Clinical Case Reports, 2018
Key Clinical Message A few cases of thyroid eye disease following alemtuzumab therapy have been described in patients with multiple sclerosis. Our patient is the first case of Graves’ orbitopathy after alemtuzumab conditioning for hematopoietic stem cell
Luminita Nicoleta Cima, Ioana Maria Lambrescu, Lavinia Stejereanu, Anca Colita, Reuven Or, Simona Fica   +5 more
doaj   +1 more source

Performance of apparent diffusion coefficient of medial and lateral rectus muscles in Graves' orbitopathy

, 2017
Objective The purpose of this study was to determine the performance of the apparent diffusion coefficient in the detection of involvement of the medial and lateral rectus muscles in patients with Graves' orbitopathy.
Mohamed E Moawad, Nader El-Metwaly, Amr A El-Said, Mohamed El-Hadidy, Ahmed AK Abdel Razek   +4 more
core   +1 more source

Targeted immunotherapies for Graves’ thyroidal & orbital diseases

Frontiers in Immunology
BackgroundGraves’ hyperthyroidism and its associated Graves’ orbitopathy are common autoimmune disorders associated with significant adverse health impact.
Alan Chun Hong Lee, George J. Kahaly
doaj   +1 more source

Steroid Treatment Focused Management of Graves’ Ophthalmopathy

Acta Medica Bulgarica
Graves' disease (GD) is an autoimmune disease that affects the thyroid and the eyes. Graves' ophthalmopathy (GO), an autoimmune disease, usually appears 18 months after GD diagnosis.
Condeng Y. H., Umar H., Aman A. M., Rasyid H., Bakri S., Iskandar H.   +5 more
doaj   +1 more source